Vivoryon Therapeutics: Promising Results Against Diabetic Kidney Disease
Vivoryon Therapeutics presented new data analyses at the World Congress of Nephrology, reinforcing the scientific validation of its therapeutic approach based on the inhibition of glutaminyl cyclase for the treatment of diabetic kidney diseases.
Vivoryon analyzed renal function data from two independent phase 2 studies, VIVIAD and VIVA-MIND, showing highly consistent results between the two studies. The new analyses presented at the World Congress of Nephrology confirm that the effect of varoglutamstat on eGFR (estimated glomerular filtration rate) was more significant in older participants with diabetes than in older participants without diabetes. In diabetic participants with a lower baseline eGFR, the magnitude of the effect was comparable or greater than that observed in the total population of diabetic participants. Data from a murine model of diabetic kidney disease also showed significant improvements in inflammation, glomerulosclerosis, and renal function.
Validating the Inhibition Approach
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
These results strengthen the validity of the approach of inhibiting glutaminyl cyclase to address the underlying inflammatory and fibrotic changes in diabetic kidney disease. Vivoryon is continuing the development of varoglutamstat, its flagship first-in-class QPCT/L inhibitor that can be administered orally, in patient populations with diabetes and more advanced stages of chronic kidney disease.
Related
SectorIndustrie Pharmaceutique et Biotechnologie›Biotechnologie
Context
Period
Period: 2025
Key reported figures
Revenue: 0 M€
EBITDA: null
Net income: -8,853 M€
Free cash flow: -8,461 M€
Guidance from the release
Nous sommes très optimistes que nous réaliserons un partenariat stratégique.
Pas de revenus en 2025, mais une réflexion sur la stratégie de financement.
Risks mentioned
La Société devra lever des fonds supplémentaires pour financer ses opérations.
Les pertes d'exploitation continueront au cours de l'exercice financier 2026.
Opportunities identified
L'initiation de l'étude Phase 2b DKD est envisagée.
Les données de Phase 2 sont encouragées pour le développement futur.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
